Compare TRS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRS | NVCR |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2004 | 2015 |
| Metric | TRS | NVCR |
|---|---|---|
| Price | $36.91 | $11.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $45.00 | $26.14 |
| AVG Volume (30 Days) | 404.4K | ★ 1.7M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 22.64 | N/A |
| Revenue | $645,720,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $5.16 | $12.95 |
| Revenue Next Year | $1.55 | $9.33 |
| P/E Ratio | $1.61 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $31.67 | $9.82 |
| 52 Week High | $45.43 | $21.45 |
| Indicator | TRS | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 30.84 |
| Support Level | $35.40 | $10.14 |
| Resistance Level | $40.10 | $18.43 |
| Average True Range (ATR) | 1.37 | 0.80 |
| MACD | -0.25 | -0.17 |
| Stochastic Oscillator | 18.40 | 4.97 |
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.